A premium MedTech compounder in a China-driven margin trough—mispriced like a broken growth stock, with asymmetric upside if margins normalize.
Overview
As of Jan 2026, Carl Zeiss Meditec is at a **structural inflection point**: a historically premium optical MedTech compounder facing a “transitional trough” where strong demand signals (record orders/backlog) collide with severe margin pressure. FY25 revenue reached **€2.228B** (+7.8% reported), but growth quality deteriorated—more **inorganic** (DORC acquisition) and more equipment-led, while high-margin China consumables underperformed. Profitability compressed with **EBITA margin at 11.6%**, well below historic ambitions, driven by China’s VBP expansion into IOLs (including premium lenses), integration/ramp costs, and mix shift. Leadership upheaval (two CEO disruptions) leaves Andreas Pecher as interim CEO, signaling potential cost discipline and operational tightening. Despite these headwinds, the long-term thesis remains supported by aging demographics and myopia prevalence, category-leading platforms (VISUMAX 800, KINEVO 900), and retina diversification via DORC. The stock has massively de-rated (P/E ~24x vs >60x peak; P/S ~1.4x), implying the market prices permanent impairment. The report argues it is more likely a high-quality franchise in cyclical reset with asymmetric upside if margins stabilize.